Stereotactic body radiotherapy for oligo-metastatic liver disease: influence of pre-treatment chemotherapy and histology on local tumor control

Introduction - Stereotactic body radiation therapy (SBRT) is applied in the oligometastatic setting to treat liver metastases. However, factors influencing tumor control probability (TCP) other than radiation dose have not been thoroughly investigated. Here we set out to investigate such factors wit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Klement, Rainer J. (VerfasserIn) , Boda-Heggemann, Judit (VerfasserIn) , Habermehl, Daniel (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: May 2017
In: Radiotherapy and oncology
Year: 2017, Jahrgang: 123, Heft: 2, Pages: 227-233
ISSN:1879-0887
DOI:10.1016/j.radonc.2017.01.013
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1016/j.radonc.2017.01.013
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0167814017300385
Volltext
Verfasserangaben:R.J. Klement, M. Guckenberger, H. Alheid, M. Allgäuer, G. Becker, O. Blanck, J. Boda-Heggemann, T. Brunner, M. Duma, S. Gerum, D. Habermehl, G. Hildebrandt, V. Lewitzki, C. Ostheimer, A. Papachristofilou, C. Petersen, T. Schneider, R. Semrau, S. Wachter, N. Andratschke

MARC

LEADER 00000caa a2200000 c 4500
001 1582365164
003 DE-627
005 20230427193211.0
007 cr uuu---uuuuu
008 181029s2017 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.radonc.2017.01.013  |2 doi 
035 |a (DE-627)1582365164 
035 |a (DE-576)512365164 
035 |a (DE-599)BSZ512365164 
035 |a (OCoLC)1341021823 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Klement, Rainer J.  |d 1979-  |e VerfasserIn  |0 (DE-588)137102860  |0 (DE-627)589930230  |0 (DE-576)302144714  |4 aut 
245 1 0 |a Stereotactic body radiotherapy for oligo-metastatic liver disease  |b influence of pre-treatment chemotherapy and histology on local tumor control  |c R.J. Klement, M. Guckenberger, H. Alheid, M. Allgäuer, G. Becker, O. Blanck, J. Boda-Heggemann, T. Brunner, M. Duma, S. Gerum, D. Habermehl, G. Hildebrandt, V. Lewitzki, C. Ostheimer, A. Papachristofilou, C. Petersen, T. Schneider, R. Semrau, S. Wachter, N. Andratschke 
264 1 |c May 2017 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 29.10.2018 
520 |a Introduction - Stereotactic body radiation therapy (SBRT) is applied in the oligometastatic setting to treat liver metastases. However, factors influencing tumor control probability (TCP) other than radiation dose have not been thoroughly investigated. Here we set out to investigate such factors with a focus on the influence of histology and chemotherapy prior to SBRT using a large multi-center database from the German Society of Radiation Oncology. - Methods - 452 SBRT treatments in 363 patients were analyzed after collection of patient, tumor and treatment data in a multi-center database. Histology was considered through random effects in semi-parametric and parametric frailty models. Dose prescriptions were parametrized by conversion to the maximum biologically effective dose using alpha/beta of 10Gy (BEDmax). - Results - After adjusting for histology, BEDmax was the strongest predictor of TCP. Larger PTV volumes, chemotherapy prior to SBRT and simple motion management techniques predicted significantly lower TCP. The model predicted a BED of 209±67Gy10 necessary for 90% TCP at 2years with no prior chemotherapy, but 286±78Gy10 when chemotherapy had been given. Breast cancer metastases were significantly more responsive to SBRT compared to other histologies with 90% TCP at 2years achievable with BEDmax of 157±80Gy10 or 80±62Gy10 with and without prior chemotherapy, respectively. - Conclusions - Besides dose, histology and pretreatment chemotherapy were important factors influencing local TCP in this large cohort of liver metastases. After adjusting for prior chemotherapy, our data add to the emerging evidence that breast cancer metastases do respond better to hypofractionated SBRT compared to other histologies. 
650 4 |a Frailty models 
650 4 |a Liver metastases 
650 4 |a SBRT 
650 4 |a Stereotactic radiotherapy 
650 4 |a Tumor control probability modeling 
700 1 |a Boda-Heggemann, Judit  |d 1977-  |e VerfasserIn  |0 (DE-588)1029853436  |0 (DE-627)734363087  |0 (DE-576)377699411  |4 aut 
700 1 |a Habermehl, Daniel  |d 1979-  |e VerfasserIn  |0 (DE-588)13804130X  |0 (DE-627)598882472  |0 (DE-576)305815415  |4 aut 
773 0 8 |i Enthalten in  |t Radiotherapy and oncology  |d Amsterdam [u.a.] : Elsevier Science, 1983  |g 123(2017), 2, Seite 227-233  |h Online-Ressource  |w (DE-627)306710110  |w (DE-600)1500707-8  |w (DE-576)082435731  |x 1879-0887  |7 nnas  |a Stereotactic body radiotherapy for oligo-metastatic liver disease influence of pre-treatment chemotherapy and histology on local tumor control 
773 1 8 |g volume:123  |g year:2017  |g number:2  |g pages:227-233  |g extent:7  |a Stereotactic body radiotherapy for oligo-metastatic liver disease influence of pre-treatment chemotherapy and histology on local tumor control 
856 4 0 |u http://dx.doi.org/10.1016/j.radonc.2017.01.013  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S0167814017300385  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20181029 
993 |a Article 
994 |a 2017 
998 |g 13804130X  |a Habermehl, Daniel  |m 13804130X:Habermehl, Daniel  |d 910000  |d 911400  |e 910000PH13804130X  |e 911400PH13804130X  |k 0/910000/  |k 1/910000/911400/  |p 11 
998 |g 1029853436  |a Boda-Heggemann, Judit  |m 1029853436:Boda-Heggemann, Judit  |d 60000  |d 63000  |e 60000PB1029853436  |e 63000PB1029853436  |k 0/60000/  |k 1/60000/63000/  |p 7 
999 |a KXP-PPN1582365164  |e 3029941515 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"person":[{"family":"Klement","display":"Klement, Rainer J.","role":"aut","given":"Rainer J."},{"given":"Judit","role":"aut","display":"Boda-Heggemann, Judit","family":"Boda-Heggemann"},{"display":"Habermehl, Daniel","family":"Habermehl","given":"Daniel","role":"aut"}],"id":{"eki":["1582365164"],"doi":["10.1016/j.radonc.2017.01.013"]},"name":{"displayForm":["R.J. Klement, M. Guckenberger, H. Alheid, M. Allgäuer, G. Becker, O. Blanck, J. Boda-Heggemann, T. Brunner, M. Duma, S. Gerum, D. Habermehl, G. Hildebrandt, V. Lewitzki, C. Ostheimer, A. Papachristofilou, C. Petersen, T. Schneider, R. Semrau, S. Wachter, N. Andratschke"]},"physDesc":[{"extent":"7 S."}],"recId":"1582365164","relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"recId":"306710110","id":{"issn":["1879-0887"],"zdb":["1500707-8"],"eki":["306710110"]},"title":[{"title":"Radiotherapy and oncology","subtitle":"journal of the European Society for Therapeutic Radiology and Oncology","title_sort":"Radiotherapy and oncology"}],"origin":[{"publisher":"Elsevier Science","dateIssuedKey":"1983","dateIssuedDisp":"1983-","publisherPlace":"Amsterdam [u.a.]"}],"note":["Gesehen am 30.05.15","Ungezählte Beil.: Supplement"],"pubHistory":["1.1983 -"],"disp":"Stereotactic body radiotherapy for oligo-metastatic liver disease influence of pre-treatment chemotherapy and histology on local tumor controlRadiotherapy and oncology","type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"titleAlt":[{"title":"The green journal"}],"part":{"volume":"123","extent":"7","year":"2017","pages":"227-233","text":"123(2017), 2, Seite 227-233","issue":"2"}}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"May 2017"}],"note":["Gesehen am 29.10.2018"],"title":[{"subtitle":"influence of pre-treatment chemotherapy and histology on local tumor control","title_sort":"Stereotactic body radiotherapy for oligo-metastatic liver disease","title":"Stereotactic body radiotherapy for oligo-metastatic liver disease"}]} 
SRT |a KLEMENTRAISTEREOTACT2017